LitAlert ~~

    • Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study.
    • Roubaud G, Özgüroglu M, Penel N, Matsubara N, Mehra N, Kolinsky MP, Procopio G, Feyerabend S, Joung JY, Gravis G, Nishimura K, Gedye C, Padua C, Shore N, Thiery-Vuillemin A, Saad F, van Alphen R, Carducci MA, Desai C, Brickel N, Poehlein C, Del Rosario P, Fizazi K.
    • Eur J Cancer. 2022 May 19 [2022 Jul];170:73-84. doi: 10.1016/j.ejca.2021.12.023. Epub ahead of print.

    Identifier: NCT02987543: Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study). (

    • The growing role of rucaparib in contemporary treatment of metastatic prostate cancer: a review of efficacy and guidance for side effect management.
    • Rao A, Antonarakis ES.
    • Expert Rev Anticancer Ther. 2022 May 20. doi: 10.1080/14737140.2022.2081154. Epub ahead of print.
    • Review